| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/01/2013 | US20130195890 Treatment of ms with goat serum |
| 08/01/2013 | US20130195889 Trabeculectomy outcome |
| 08/01/2013 | US20130195885 Compositions with Hematopoietic and Immune Activity |
| 08/01/2013 | US20130195884 Novel modulators of trail signalling |
| 08/01/2013 | US20130195883 Use of vap-1 inhibitors for treating fibrotic conditions |
| 08/01/2013 | US20130195882 Mcpip protection against osteoclast production |
| 08/01/2013 | US20130195881 Potent, stable and non-immunosuppressive anti-cd4 antibodies |
| 08/01/2013 | US20130195875 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy |
| 08/01/2013 | US20130195874 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| 08/01/2013 | US20130195873 Carbohydrate hapten-based anti-cancer vaccines and antibody drugs |
| 08/01/2013 | US20130195871 Dual variable domain immunoglobulins and uses thereof |
| 08/01/2013 | US20130195870 ERBB3 Mutations In Cancer |
| 08/01/2013 | US20130195868 Treating surface of the eye disorders |
| 08/01/2013 | US20130195867 Rna-coded antibody |
| 08/01/2013 | US20130195863 Methods and Pharmaceutical Compositions for the Treatment of Bone Density Related Diseases |
| 08/01/2013 | US20130195857 Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer |
| 08/01/2013 | US20130195856 Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| 08/01/2013 | US20130195855 Methods of antagonizing signal transduction in dorsal root ganglion cells |
| 08/01/2013 | US20130195854 Predictive biomarker for cancer treatment with adcc-enhanced antibodies |
| 08/01/2013 | US20130195853 Modulators of candida hyphal morphogenesis and uses thereof |
| 08/01/2013 | US20130195852 Use of inhibitors of bruton's tyrosine kinase (btk) |
| 08/01/2013 | US20130195851 Articles of manufacture and methods for co-administration of antibodies |
| 08/01/2013 | US20130195847 Treatment with anti-vegf antibodies |
| 08/01/2013 | US20130195846 Combination therapy with type i and type ii anti-cd20 antibodies |
| 08/01/2013 | US20130195840 Therapeutics and processes for treatment of immune disorders |
| 08/01/2013 | US20130195794 Cancer vaccine |
| 08/01/2013 | US20130195754 IL-l BINDING PROTEINS |
| 08/01/2013 | US20130195751 Self-assembed conjugate and use thereof |
| 08/01/2013 | DE102012200836B3 Digesting flower pollen useful for treating allergic symptoms, e.g. sneezing and watery eyes, comprises providing pollen to be broken down in mixture with lactose and circulating such that lactose particles are able to cut open pollen |
| 08/01/2013 | CA2857967A1 Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration |
| 08/01/2013 | CA2856443A1 Vaccines against clostridium difficile comprising recombinant toxins |
| 07/31/2013 | EP2620452A1 Binding members for IGE molecules |
| 07/31/2013 | EP2620450A2 Anti-CTLA-4 antibody compositions |
| 07/31/2013 | EP2620449A1 Anti-ephrin-b2 antibody and use thereof |
| 07/31/2013 | EP2620423A1 Improved methods for preparing squalene |
| 07/31/2013 | EP2620159A1 Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria |
| 07/31/2013 | EP2620158A1 Adjuvants for use in vaccination |
| 07/31/2013 | EP2620157A2 Vaccine nanotechnology |
| 07/31/2013 | EP2619571A2 Human b1 cells and uses thereof |
| 07/31/2013 | EP2619328A2 Top2a inhibition by temozolomide useful for predicting gbm patient's survival |
| 07/31/2013 | EP2619226A2 Carrier immunoglobulins and uses thereof |
| 07/31/2013 | EP2619219A2 Peptides |
| 07/31/2013 | EP2618843A2 Novel hiv-1 broadly neutralizing antibodies |
| 07/31/2013 | EP2618842A1 Novel immunostimulatory method |
| 07/31/2013 | EP2618841A1 Bvdv vaccine |
| 07/31/2013 | EP2618840A2 Recombinant viral vectors and methods for inducing an immune response to yellow fever virus |
| 07/31/2013 | EP2618839A1 Methods to produce bunyavirus replicon particles |
| 07/31/2013 | EP2618838A1 Therapeutic vaccination against active tuberculosis |
| 07/31/2013 | EP2618837A1 Recombinant mycobacterium as vaccine for use in humans |
| 07/31/2013 | EP2618836A1 Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis and related proteins, peptides and compositions |
| 07/31/2013 | EP2618835A1 Antigen-specific t cell receptors and t cell epitopes |
| 07/31/2013 | EP2618834A1 A method for keeping a foot-and-mouth disease vaccine available for emergency vaccination |
| 07/31/2013 | EP2618833A2 Breast cancer therapeutics |
| 07/31/2013 | EP2618817A2 Liposome targeting compounds and related uses |
| 07/31/2013 | EP2411043B1 Treatment of cancer with immunostimulatory hiv tat derivative polypeptides |
| 07/31/2013 | EP1476185B1 Antibodies to cd40 |
| 07/31/2013 | CN1989240B Vaccine comprising an attenuated pestivirus |
| 07/31/2013 | CN1910198B Tumor antigens for prevention and/or treatment of cancer |
| 07/31/2013 | CN103228787A Fusion protein for secretory protein expression |
| 07/31/2013 | CN103228674A Methods and compositions for neural disease immunotherapy |
| 07/31/2013 | CN103228673A Anti-human trop- antibody having antitumor activity in vivo |
| 07/31/2013 | CN103228327A Methods for capturing virus like particles from plants using expanded chromatography |
| 07/31/2013 | CN103228295A Methods of limiting microvascular damage following acute myocardial ischemia |
| 07/31/2013 | CN103228294A 疫苗 Vaccine |
| 07/31/2013 | CN103228293A Vaccine formulation for prophylaxis and treatment of chandipura virus infections in mammals |
| 07/31/2013 | CN103228292A Vaccine against n. meningitidis |
| 07/31/2013 | CN103228291A Combination therapy for B cell lymphomas |
| 07/31/2013 | CN103228284A Methods and compositions for preventing a condition |
| 07/31/2013 | CN103228159A Fat composition for programming immune response |
| 07/31/2013 | CN103224914A Construction and application of recombinant peste des petits ruminants virus expressing fused exogenous epitope N protein |
| 07/31/2013 | CN103224913A Duck plague live vaccine and preparation method thereof |
| 07/31/2013 | CN103224562A Epitope regions of a thyrotrophin (TSH) receptor, and antibodies thereto |
| 07/31/2013 | CN103224559A Human HIV broad spectrum neutralization antibody A16, associated biological material and applications thereof |
| 07/31/2013 | CN103224548A Polypeptide for preparing cattle foot-and-mouth disease ASIAI type peptide vaccine and preparing method and use thereof |
| 07/31/2013 | CN103223167A Methods of reducing eosinophil levels |
| 07/31/2013 | CN103223166A Application of human stem cell self-renewal support factor in liver cancer targeting treatment |
| 07/31/2013 | CN103223165A Reducer of immunosuppression by tumor cell and antitumor agent using the same |
| 07/31/2013 | CN103223164A Water-in-oil-in-water adjuvant vaccine and preparation method thereof |
| 07/31/2013 | CN103223163A IPV-DPT Vaccine |
| 07/31/2013 | CN103223162A Application of H3N2 canine influenza virus CGD1 |
| 07/31/2013 | CN102659926B Pc-E polypeptide inhibiting aspergillus fumigatus from adhering to cornea |
| 07/31/2013 | CN102584949B Pc-C polypeptide inhibiting aspergillus fumigatus from adhering to cornea |
| 07/31/2013 | CN102517232B Resistance marker-free porcine actinobacillus pleuropneumoniae double-gene defective strain, construction method and application thereof |
| 07/31/2013 | CN102516373B Pneumococcal surface protein A without human homology, purification method and application thereof |
| 07/31/2013 | CN102210646B Human rabies vaccine gel and preparation method thereof |
| 07/31/2013 | CN102199571B Recombinant Bordetella bronchiseptica strain expressing ORF2 gene fragment of porcine circovirus type 2, vaccine and application |
| 07/31/2013 | CN102134562B Construction and screening of rabies virus Evelyn-Rokitnicki-Abelseth (ERA) attenuated live vaccine candidate strain |
| 07/31/2013 | CN101955941B Porcine interferon gene family and application thereof in blue-ear porcine disease resistant medicament and vaccine adjuvant |
| 07/31/2013 | CN101920008B Preparation containing Abeta 40 polypeptide and aluminum adjuvant and method for purifying Abeta 40 polypeptide |
| 07/31/2013 | CN101883584B Allergen desensitization method |
| 07/31/2013 | CN101850112B Novel recombinant vaccine used for preventing tuberculosis |
| 07/31/2013 | CN101850111B Novel vaccine used for preventing tuberculosis |
| 07/31/2013 | CN101822829B Recombinant BCG vaccine for tuberculosis prevention |
| 07/31/2013 | CN101695572B Method for producing pseudorabies attenuated vaccine by using bioreactor and pseudorabies attenuated vaccine product |
| 07/31/2013 | CN101668853B Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them |
| 07/31/2013 | CN101379192B Anti-Met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products |
| 07/31/2013 | CN101124247B Antibodies directed against amyloid-beta peptide and uses thereof |
| 07/31/2013 | CN101039691B Compositions and methods for treating neurological disorders |
| 07/31/2013 | CA2766474A1 Post-exposure therapy of influenza a infections |
| 07/30/2013 | USRE44399 One dose vaccination with Mycoplasma hyopneumoniae |